Five Prime Therapeutics (NASDAQ:FPRX) shares were trading higher on Thursday after the company presented first preclinical data on Anti-CCR8 antibody FPA157.
Five Prime Therapeutics is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company's product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities.
Five Prime Therapeutics shares traded up 24.22% at $34.53 on Thursday during the time of publication. The stock has a 52-week high of $24.48 and a 52-week low of $1.75.